# Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation

> **NCT02113891** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Assistance Publique - Hôpitaux de Paris**

## Conditions studied

- Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT02113891
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-02
- **Primary completion:** 2017-07
- **Final completion:** 2017-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** disengagement of the sponsor Alexion Pharmaceuticals
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02113891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02113891, "Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02113891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*